[1] URBICH M, GLOBE G, PANTIRI K, et al. A systematic review of medical costs associated with heart failure in the USA (2014-2020)[J]. Pharmacoeconomics, 2020, 38(11): 1219-1236.
[2] CHARLE C J, RADEMAKER M T, SCOTT N J A, et al. Large animal models of heart failure: Reduced vs. Preserved Ejection Fraction [J]. Animals: Basel, 2020, 10(10): 1906-1914.
[3] BEI Y, CHEN T, BANCIU D, et al. Circulating exosomes in Cardiovascular Diseases[J]. Adv Exp Med Biol, 2017, 998: 255-269.
[4] WU R, GAO W, YAO K, et al. Roles of exosomes derived from immune cells in cardiovascular diseases[J]. Front Immunol, 2019, 10: 648.
[5] TIKHOMIROV R, O′ DONNELL B R, CATAPANO F, et al. Exosomes: From Potential Culprits to New Therapeutic Promise in the Setting of Cardiac Fibrosis [J]. Cells, 2020, 9(3):592.
[6] LYU L, WANG H, LI B, et al. A critical role of cardiac fibroblast-derived exosomes in activating renin angiotensin system in cardiomyocytes[J]. J Mol Cell Cardiol, 2015, 89(Pt B):268-279.
[7] KHAN M, NICKOLOFF E, ABRAMOVA T, et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction[J]. Circ Res, 2015, 117(1): 52-64.
[8] WANG L, LIU J, XU B, et al. Reducedexosome miR-425 and miR-744 in the plasma represents the progression of fibrosis and heart failure[J]. Circ Res, 2015, 117(1):52-64.
[9] YUAN Y, DU W, LIU J, et al.Stem cell-derived exosome in cardiovascular diseases: Macro Roles of Micro Particles [J].Front Pharmacol, 2018, 9: 547.
[10] YANCYC W, JESSUP M, BOZKURT B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J]. J Card Fail, 2017, 23(8):628-651.
[11] PFEIFER P, WERNER N, JANSEN F. Role and function of micrornas in extracellular vesicles in cardiovascular biology [J]. Biomed Res Int, 2015, 2015:161393.
[12] EMANUELL C, SHEARN I, LAFTAH A, et al. Coronary artery-bypass-graft surgeryincreases the plasma concentration of exosomes carrying a cargo of cardiac microRNAs: An example of exosome trafficking out of the human heart with potential for cardiac biomarker discovery [J]. PLoS One, 2016, 11(4):e0154274.
[13] BEG F, WANG R, SAEED Z, et al. Inflammation-associated microRNA changes in circulating exosomes of heart failure patients[J]. BMC Res Notes, 2017, 10 (1):751.
[14] WU T, CHEN Y C, DU Y T, et al. Circulating exosomal miR-92b-5p is a promising diagnostic biomarker of heart failure with reduced ejection fraction patients hospitalized for acute heart failure [J]. J Thorac Dis, 2018, 10(11):6211-6220.
[15] BI S J, WANG C Y, JIN Y W, et al. Correlation between serum exosome derived miR-208a and acute coronary syndrome[J]. Int J Clin Exp Med, 2015, 8(3):4275-4280.
[16] NAKAMYRA Y, KITA S, TANAKA Y, et al. Adiponectin stimulates exosome release to enhance mesenchymal stem-cell-driven therapy of heart failure in mice[J]. Mol Ther, 2020, 28(10):2203-2219.
[17] LUTHER K M, HAAR L, MCGUINNESS M, et al. Exosomal miR-21a-5p mediates cardioprotection by mesenchymal stem cells[J]. J Mol Cell Cardiol, 2018, 119:125-137.
[18] SINGLA D K, JOHNSON T A, DARGANI Z T. Exosome treatment enhances anti-inflammatory M2 macrophages and reduces inflammation-induced pyroptosis in doxorubicin-induced cardiomyopathy [J]. Cells, 2019, 8(10):1224. |
